Tags : Teva Canada

PharmaShots’ Key Highlights of Third Quarter 2019

The third quarter of 2019 has ended with major acquisitions in the pharma and biotech industry along with multiple approvals. Starting with the latest acquisition where Biocon Biologics acquires Pfizer’s Research Facility for expansion of its R&D footprints with the acceleration of the development of its biosimilars from lab to pilot scale. Previously, Amgen acquired […]Read More

Teva Canada’s Herzuma (biosimilar, trastuzumab) Receives Health Canada Approval for

Shots: Health Canada has granted notice of compliance for Teva Canada’s Herzuma for the treatment of early breast cancer (EBC), metastatic breast cancer (MBC) and metastatic gastric cancer (MGC) in Canada The Health Canada NOC is based on efficacy, safety, quality, immunogenicity, PK/PD data from non-clinical and clinical studies, demonstrating that Herzuma and Herceptin has […]Read More